Greetings, MAPS members!
We hope you’re enjoying the Spring 2003 MAPS bulletin! If you haven’t received your copy, let us know. (International members will have to wait a bit longer.)
In an effort to communicate with the MAPS community more frequently, we’re going to be sending occasional emails with updates on MAPS events and projects.
This edition, we’ve got two items, both related to medical marijuana. The first is an announcement of an amicus curiae brief filed by MAPS and the Marijuana Policy Project, in support of the constitutional rights of patients to use cannabis. The second is a press release announcing the results of the vaporizer study sponsored by MAPS and California NORML.
Enjoy! Please let us know if you’d like to be removed from our email update list.
Best wishes –
Brandy
Brandy Doyle
Director of Special Projects
MAPS
1. Filing of Amicus Curiae brief in support of patients’ constitutional right to cannabis
On 4/30/03, MAPS and the Marijuana Policy Project filed a “friend of court” brief with the US Court of Appeals for the Ninth Circuit, in the case of Angel Raich et al. v. John Ashcroft as US Attorney General and Asa Hutchinson, Administrator of the DEA.
The document outlines the political obstacles blocking medical marijuana research, arguing that because research is so difficult to conduct, the court should not make a decision restricting patients’ access to cannabis based on the illusion of a well-functioning approval process. The brief can be found online at http://maps.org/mmj/MAPS_brief_050603.pdf
2. California NORML/ MAPS Release – May 2, 2003 Study Shows Vaporizer Can Drastically Reduce Toxins in Marijuana Smoke
Harmful toxins in marijuana smoke can be effectively avoided by a vaporization device, according to a new study by California NORML and MAPS (Multidisciplinary Association for Psychedelic Studies) with support from a grant from the MPP (Marijuana Policy Project). The study can be found online at https://maps.org/mmj/vaporizerstudy4.15.03.pdf. The study, conducted by Chemic Labs in Canton, Mass., tested vapors from cannabis heated in an herbal vaporizer known as the Volcano (manufactured by Storz & Bickel GmbH&Co. KG, Tuttlingen, Germany; http://www.storz-bickel.com) and compared them to smoke produced by combusted marijuana. The Volcano is designed to heat material to temperatures of 130 to 230 C (266 to 446 F) where medically active vapors are produced, but below the threshold of combustion where smoke is formed.
The vapors from the Volcano were found to consist overwhelmingly of THC, the major active component in marijuana, whereas the combusted smoke contained over 100 other chemicals, including several polynuclear aromatic hydrocarbons (PAHs), carcinogenic toxins that are common in tobacco smoke. The respiratory hazards of marijuana and tobacco smoke are due to toxic byproducts of combustion, not the active ingredients in the plant, known as cannabinoids.
The study suggests that medical marijuana patients can avoid the respiratory hazards of smoking by using a vaporizer. In its 1999 report on medical marijuana, the Institute of Medicine recommended against long-term use of smoked marijuana because of the health risks of smoking. However, the IOM failed to take account of vaporizers.
Previous studies have found that vaporizers can reduce harmful toxins in cannabis smoke. However, this is the first study to analyze the gas phase of the vapor for a wide range of toxins. A previous NORML/MAPS study conducted by Chemic Labs found that a vaporizer known as the M-1 Volatizer (http://www.volatizer.com”>http:// http://www.volatizer.com) completely eliminated three specific toxins (naphthalene, benzene and toluene) in the solid phase of the vapor (D. Gieringer, “Cannabis Vaporization: A Promising Strategy for Smoke Harm Reduction,” Journal of Cannabis Therapeutics Vol. 1 #3-4: 153-70 (2001); http://www.canorml.org/ healthfacts/vaporizerstudy1.html).
The new study used a gas chromatograph mass spectrometer (GCMS) to examine the gas components of the vapor. The analysis showed that the Volcano vapor was remarkably clean, consisting 95% of THC with traces of cannabinol (CBN), another cannabinoid. The remaining 5% consisted of small amounts of three other components:
One suspected cannabinoid relative, one suspected PAH, and caryophyllene, a fragrant oil in cannabis and other plants. In contrast over 111 different components appeared in the gas of the combusted smoke, including a half dozen known PAHs.
Non-cannabinoids accounted for as much as 88% of the total gas content of the smoke.
The study used standard NIDA cannabis with 4% THC content. A quantitative analysis found that the Volcano delivered 46% of the THC into vapor following three 45-second exposures of the sample to the heat. This compares favorably with the typical efficiency of marijuana cigarettes as observed in other studies, which depending on conditions can fall below 25% due to loss of THC in sidestream smoke.
An important feature of the Volcano is that it uses a balloon to capture the vapor, thereby avoiding leakage to the air. It is possible that higher THC efficiencies could have been reached with the Volcano by stirring the sample around and exposing it to more heat.
The combusted sample achieved a relatively high THC efficiency of 78% upon complete combustion. The high efficiency seems due to the fact that the sample was completely consumed by combustion, and that smoke leakage was effectively prevented by the laboratory setup. Similar conditions do not obtain under normal circumstances when a marijuana cigarette is smoked and much of the THC is lost to the air or left in the unburned “roach.”
Two other cannabinoids, cannabidiol (CBD) and cannabinol (CBN), were detected in the NIDA cannabis in trace amounts of 0.1%.
Both the Volcano and combustion delivered an apparent increase in CBD and CBN, but the variance of the data was too high to reach statistically significant conclusions.
Sponsors believe that the study results lend support for wider use of vaporizers by medical marijuana patients and researchers. At present, the only FDA-approved method for administering marijuana to human research subjects is via smoking NIDA cigarettes. NORML and MAPS are supporting efforts to have vaporizers approved by the FDA. As a first step in this effort, Dr. Donald Abrams of the University of California, San Francisco, has submitted a grant proposal to the California Center for Medical Cannabis Research in San Diego to test the Volcano in human subjects. If the protocol is funded and the Volcano approved by the FDA for human research, it will be the first human study using a vaporizer. If the FDA requests additional laboratory data about the Volcano@, additional funding may be necessary.
For more information on vaporizers, see https://maps.org/mmj/vaporizer.html